Start Over

Reply to Caccialanza et al

Authors :: P. Boisselier
Jean Bourhis
Pierre Senesse
Marie Vinches
S. Thezenas
N. Flori
Institut du Cancer de Montpellier (ICM)
Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV)
Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM)
CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
KARLI, Mélanie
Source :: The American Journal of Clinical Nutrition, The American Journal of Clinical Nutrition, Oxford University Press, 2021, 113 (4), pp.1054-1055. ⟨10.1093/ajcn/nqaa425⟩
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.
Abstract: International audience; A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX. Boisselier P, Kaminsky MC, Thézenas S, Gallocher O, Lavau-Denes S, Garcia-Ramirez M, Alfonsi M, Cupissol D, de Forges H, Janiszewski C, Geoffrois L, Sire C, Senesse P; Head and Neck Oncology and Radiotherapy Group (GORTEC). Am J Clin Nutr. 2020 Dec 10;112(6):1523-1531. doi: 10.1093/ajcn/nqaa227. PMID: 32936874 Clinical Trial. Immunonutrition in head and neck cancer patients undergoing chemoradiotherapy: an alternative approach for overcoming potential bias. Caccialanza R, Cereda E, Orlandi E, Filippi AR, Comoli P, Alberti A, Imarisio I, Pedrazzoli P, Bossi P. Am J Clin Nutr. 2021 Apr 6;113(4):1053-1054. doi: 10.1093/ajcn/nqaa421. PMID: 33822867 No abstract available.